Mark Abbott, Ph.D.

Mark Abbott gained his PhD from Nottingham University in the UK studying D2 dopamine receptors. His postdoctoral studies with the Medical Research Council were focussed on mammalian carbohydrate binding proteins. He then spent over 20 years in the pharmaceutical industry as a protein biochemist in AstraZeneca. He led teams providing protein expression, purification and QC expertise into drug discovery projects in multiple different research areas in both small molecule and biologics projects. He has managed both technology and biologics drug discovery projects within global Pharma. He has more than 30 peer reviewed publications on a very wide range of proteins and their use particularly in drug discovery.

Mark is the founder and CEO of Peak Proteins which is a rapidly growing contract research organisation providing tailored proteins, structural biology and protein mass spectrometry services to a wide variety of clients across the world.